How have ICCC shares performed in 2024?

ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC stock has decreased by 0.8% and is now trading at $5.05. View the best growth stocks for 2024 here .

When is ImmuCell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ICCC earnings forecast .

How can I listen to ImmuCell's earnings call?

ImmuCell will be holding an earnings conference call on Friday, May 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2581533".

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) issued its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $5.10 million for the quarter. ImmuCell had a negative net margin of 33.05% and a negative trailing twelve-month return on equity of 21.79%.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell updated its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) , Agile Therapeutics (AGRX) , Biocept (BIOC) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Genocea Biosciences (GNCA) , Idera Pharmaceuticals (IDRA) and Pfizer (PFE) .

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free ICCC Stock Alerts

$5.05

-0.02 (-0.39%)

(As of 12:59 PM ET)

Compare

Today's Range: $5.05
▼
$5.16
50-Day Range: $4.90
▼
$5.37
52-Week Range: $4.26
▼
$6.05

Volume: 1,084 shs
Average Volume: 7,627 shs
Market Capitalization: $39.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get ImmuCell alerts:

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About ImmuCell Stock (NASDAQ:ICCC)

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ICCC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ICCC Stock News Headlines

April 12, 2024 | americanbankingnews.com

ImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average of $5.03

April 12, 2024 | americanbankingnews.com

ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average of $5.03

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 10, 2024 | finanznachrichten.de

ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

April 9, 2024 | msn.com

ImmuCell reports preliminary Q1 sales, stock climbs 7%

April 9, 2024 | markets.businessinsider.com

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

April 9, 2024 | globenewswire.com

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

February 29, 2024 | finance.yahoo.com

ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

February 28, 2024 | seekingalpha.com

ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript

February 27, 2024 | globenewswire.com

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

February 16, 2024 | finance.yahoo.com

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

February 16, 2024 | globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

January 9, 2024 | benzinga.com

ImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and Dates

January 9, 2024 | finanznachrichten.de

ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

January 8, 2024 | msn.com

ImmuCell says total sale for year ended December falls 6% Y/Y

January 8, 2024 | finance.yahoo.com

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

November 15, 2023 | finance.yahoo.com

ImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call Transcript

November 14, 2023 | seekingalpha.com

ImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript

November 13, 2023 | msn.com

ImmuCell GAAP EPS of -$0.12, revenue of $5.39M

November 13, 2023 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

November 7, 2023 | finance.yahoo.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

October 5, 2023 | finance.yahoo.com

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

September 5, 2023 | finance.yahoo.com

ImmuCell Corporation (ICCC) Stock Historical Prices & Data - Yahoo Finance

August 29, 2023 | finance.yahoo.com

ImmuCell Announces Submission of CMC Technical Section to the FDA

August 11, 2023 | seekingalpha.com

ImmuCell Corporation (ICCC) Q2 2023 Earnings Call Transcript

August 11, 2023 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

See More Headlines

Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: NASDAQ:ICCC
CUSIP: N/A
CIK: 811641
Web: www.immucell.com
Phone: (207) 878-2770
Fax: 207-878-2117
Employees: 74
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,780,000.00
Net Margins: -33.05%
Pretax Margin: -33.02%
Return on Equity: -21.79%
Return on Assets: -13.16%

Debt

Debt-to-Equity Ratio: 0.42
Current Ratio: 2.73
Quick Ratio: 0.87

Sales & Book Value

Annual Sales: $17.47 million
Price / Sales: 2.24
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.23 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 7,750,000
Free Float: 7,263,000
Market Cap: $39.14 million
Optionable: Not Optionable
Beta: 0.59

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Michael F. Brigham (Age 63)
President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Comp: $395.24k
Ms. Bobbi Jo Brockmann (Age 47)
VP of Sales & Marketing and Director
Comp: $323.52k
Elizabeth S. Toothaker
Director of Finance & Administration and Controller
Mr. A. Gustavo Scaffa
Senior Director of Quality
John W. Zinckgraf
Director of Product Development

Key Competitors

View All Competitors

Institutional Ownership

Northern Trust Corp
Bought 19,781 shares on 2/13/2024
Ownership: 0.421%

View All Institutional Transactions

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed in 2024?: ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC stock has decreased by 0.8% and is now trading at $5.05.
View the best growth stocks for 2024 here.
When is ImmuCell's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ICCC earnings forecast.
How can I listen to ImmuCell's earnings call?: ImmuCell will be holding an earnings conference call on Friday, May 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2581533".
How were ImmuCell's earnings last quarter?: ImmuCell Co. (NASDAQ:ICCC) issued its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $5.10 million for the quarter. ImmuCell had a negative net margin of 33.05% and a negative trailing twelve-month return on equity of 21.79%.

What guidance has ImmuCell issued on next quarter's earnings?: ImmuCell updated its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million.
What other stocks do shareholders of ImmuCell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).
How do I buy shares of ImmuCell?: Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICCC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial